---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005023"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-07-24T23:59:59+00:00"
generated_at: "2026-05-31T17:02:46.896591+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CNS Pharmaceuticals gets final Nasdaq extension to Aug 12 for equity compliance

## Summary
- Nasdaq Panel granted extension until August 12, 2024 to meet $2.5M stockholders' equity requirement.
- Company previously failed to comply with Listing Rule 5550(b) and requested hearing.
- This is the full extent of the Panel's discretion; failure to comply may lead to delisting.

## SEC filing metadata
- accession: 0001683168-24-005023
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-07-24T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005023/0001683168-24-005023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005023/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005023
- JSON: https://secwatch.observer/filing/0001683168-24-005023.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.